GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Shiller PE Ratio

Ryvu Therapeutics (WAR:RVU) Shiller PE Ratio : 6.35 (As of Jun. 23, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Shiller PE Ratio?

As of today (2024-06-23), Ryvu Therapeutics's current share price is zł50.10. Ryvu Therapeutics's E10 for the quarter that ended in Mar. 2024 was zł7.89. Ryvu Therapeutics's Shiller PE Ratio for today is 6.35.

The historical rank and industry rank for Ryvu Therapeutics's Shiller PE Ratio or its related term are showing as below:

WAR:RVU' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.14   Med: 7.22   Max: 9.18
Current: 6.52

During the past years, Ryvu Therapeutics's highest Shiller PE Ratio was 9.18. The lowest was 3.14. And the median was 7.22.

WAR:RVU's Shiller PE Ratio is ranked better than
93.51% of 154 companies
in the Biotechnology industry
Industry Median: 30.45 vs WAR:RVU: 6.52

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ryvu Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was zł-0.800. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is zł7.89 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ryvu Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Ryvu Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Shiller PE Ratio Chart

Ryvu Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 8.70 6.32 7.27

Ryvu Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.30 7.49 8.20 7.27 6.99

Competitive Comparison of Ryvu Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Ryvu Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Shiller PE Ratio falls into.



Ryvu Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ryvu Therapeutics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=50.10/7.89
=6.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ryvu Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.8/149.0435*149.0435
=-0.800

Current CPI (Mar. 2024) = 149.0435.

Ryvu Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.144 101.180 0.212
201409 0.156 100.611 0.231
201412 0.179 100.122 0.266
201503 9.700 100.041 14.451
201506 0.157 100.448 0.233
201509 0.120 99.634 0.180
201512 0.104 99.471 0.156
201603 -0.184 98.983 -0.277
201606 -0.076 99.552 -0.114
201609 0.196 99.064 0.295
201612 0.262 100.366 0.389
201703 39.500 101.018 58.279
201706 0.201 101.180 0.296
201709 0.067 101.343 0.099
201712 -0.198 102.564 -0.288
201803 1.237 102.564 1.798
201806 -0.253 103.378 -0.365
201809 -0.726 103.378 -1.047
201812 -1.820 103.785 -2.614
201903 -0.602 104.274 -0.860
201906 -0.728 105.983 -1.024
201909 -0.245 105.983 -0.345
201912 19.461 107.123 27.077
202003 -0.270 109.076 -0.369
202006 -0.269 109.402 -0.366
202009 -0.725 109.320 -0.988
202012 -0.612 109.565 -0.833
202103 -0.739 112.658 -0.978
202106 -1.321 113.960 -1.728
202109 -1.243 115.588 -1.603
202112 -0.997 119.088 -1.248
202203 -1.400 125.031 -1.669
202206 -2.000 131.705 -2.263
202209 -0.600 135.531 -0.660
202212 -0.500 139.113 -0.536
202303 -0.800 145.950 -0.817
202306 -1.200 147.009 -1.217
202309 -0.800 146.113 -0.816
202312 -1.200 147.741 -1.211
202403 -0.800 149.044 -0.800

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ryvu Therapeutics  (WAR:RVU) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ryvu Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ryvu Therapeutics (WAR:RVU) Business Description

Traded in Other Exchanges
N/A
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics (WAR:RVU) Headlines

No Headlines